News – Page 1071 – Endpoints News

What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll

8 years ago

Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis

8 years ago

BioNTech raises mammoth $270M A round, nearing $1B mark as investors continue a love affair with mRNA

8 years ago

Pfizer lines up an $830M alliance with Arvinas on protein degradation

8 years ago

Allergan axing 1,000-plus jobs, prepping for a painful onslaught of Restasis knockoffs

8 years ago

Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup ...

8 years ago

All in: Boehringer Ingelheim more than doubles its venture fund to €250M

8 years ago

Pfizer doubles down on Sangamo’s zinc finger tech, adding ALS to a mix of gene therapy alliances

8 years ago

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug

8 years ago

Upstart Expansion bags a $55M launch round to join the hunt for RNA-targeting small molecules

8 years ago

John Mendlein steps in to help focus on the big picture at a fast-growing Moderna

8 years ago

Biogen vet Jean-Paul Kress takes the reins at NYC's Syntimmune

8 years ago

A better approach to growth factors? Scholar Rock raises $47M on SMA promise

8 years ago

Microsoft, Google back DNAnexus' Big Data work with $58M; Novartis, Temasek back $50M round for Pear’s med apps

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

8 years ago

Ex-Pfizer CEO's startup Centrexion gets $67M for PhIII painkiller

8 years ago

Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins

8 years ago

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

8 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

8 years ago

J&J’s big blockbuster hopeful esketamine scores high for major depression — but side effects haunt results

8 years ago

On a deal spree, Mallinckrodt bags Sucampo and two late-stage rare disease drugs for $1.2B

8 years ago

Novartis' Tafinlar/Mekinist combo for melanoma gets priority review designation; Fosun Pharma backs joint venture's ...

8 years ago

Synergy CEO passes torch to CCO Troy Hamilton; President Steven Kafka resigns from Foundation; AbbVie vet John ...

8 years ago

First page Previous page 1068 1069 107010711072 1073 1074 Next page Last page